title: Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate the impact of highly active antiretroviral therapy (HAART) on survival in HIV infected patients with non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  All consecutive HIV infected patients with NSCLC diagnosed between 06/1996 and 03/2007 at two University hospitals in Paris (France) were prospectively followed until death. The association between survival and clinical and biological factors was analyzed by univariate and multivariate models. Survival analysis was performed by Kaplan-Meier estimates and the Cox proportional hazards regression model.
  
  
  RESULTS
  During the study period, NSCLC was diagnosed in 49 consecutive HIV infected patients (median age 46 years); 84% had advanced disease. Median survival was 8.1 months (range 5-10 months). In multivariate analysis, baseline parameters with significant positive impact on survival included performance status (PS) < or =1 (HR=0.2, 95%CI [0.09, 0.46], p=0.0001), stage I-II disease (HR=0.15, 95%CI [0.04, 0.53], p=0.003), and use of HAART (HR=0.4, 95%CI [0.2, 0.9], p=0.027).
  
  
  CONCLUSIONS
  HAART is a good prognostic factor for survival in HIV infected patients with NSCLC. Stage of disease and PS are two other valid survival prognostic factors.
authors.affiliation: Service de Pneumologie et Réanimation, Hôpital Tenon, APHP and Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France. armelle.lavole@tnn.aphp.fr
authors.forename: Armelle
authors.initials: A
authors.lastname: Lavolé
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaïd
authors.forename: Laurence
authors.initials: L
authors.lastname: Baudrin
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.forename: Gilles
authors.initials: G
authors.lastname: Raguin
authors.forename: Gilles
authors.initials: G
authors.lastname: Pialoux
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
authors.forename: Bernard
authors.initials: B
authors.lastname: Milleron
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D014779:Virus Replication / Q000187:drug effects